Cargando…
Activity of Galidesivir in a Hamster Model of SARS-CoV-2
Coronavirus disease 2019 (COVID-19) has claimed the lives of millions of people worldwide since it first emerged. The impact of the COVID-19 pandemic on public health and the global economy has highlighted the medical need for the development of broadly acting interventions against emerging viral th...
Autores principales: | Taylor, Ray, Bowen, Richard, Demarest, James F., DeSpirito, Michael, Hartwig, Airn, Bielefeldt-Ohmann, Helle, Walling, Dennis M., Mathis, Amanda, Babu, Yarlagadda S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780270/ https://www.ncbi.nlm.nih.gov/pubmed/35062212 http://dx.doi.org/10.3390/v14010008 |
Ejemplares similares
-
An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral
por: Julander, Justin G., et al.
Publicado: (2021) -
Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters
por: Westover, Jonna B., et al.
Publicado: (2018) -
Oral Administration of Universal Bacterium-Vectored Nucleocapsid-Expressing COVID-19 Vaccine is Efficacious in Hamsters
por: Jia, Qingmei, et al.
Publicado: (2023) -
Susceptibility of Wild Canids to SARS-CoV-2
por: Porter, Stephanie M., et al.
Publicado: (2022) -
Susceptibility of livestock to SARS-CoV-2 infection
por: Bosco-Lauth, Angela M., et al.
Publicado: (2021)